Fig. 3: Kaplan Meier curve showing overall survival since treatment initiation among 29 patients who received Pembrolizumab.
Medial overall survival was 20.43 weeks (95% confidence interval 12.86- not estimated).
Fig. 3: Kaplan Meier curve showing overall survival since treatment initiation among 29 patients who received Pembrolizumab. | British Journal of Cancer
